RET
FDA Grants Full Approval to Eli Lilly's Retevmo in RET-Mutant Medullary Thyroid Cancer
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
Eli Lilly Nabs Full FDA Approval for Retevmo in RET Fusion-Positive Thyroid Cancer
In converting a 2020 accelerated approval to a full approval, the agency lowered the RET inhibitor's age restriction from 12 years old to 2 years old.
FDA Lowers Pediatric Age for Eli Lilly's Retevmo
The RET inhibitor can now be given to children with RET-altered cancers as young as 2 years old.